Healthcare Industry Deep Dive: Complete Framework for Case Interviews

Healthcare cases account for approximately 15% of MBB consulting interviews and are among the most complex due to multiple stakeholders, heavy regulation, and intricate payment systems. Unlike consumer industries where pricing follows market dynamics, healthcare operates under a web of government rules, insurance negotiations, and clinical considerations. This guide provides the complete framework to navigate healthcare cases with confidence.

Products and Services Landscape

Healthcare is not one industry — it’s an interconnected ecosystem of sub-sectors with fundamentally different business models. Identifying which sub-sector your case addresses in the first 60 seconds is critical.

Sub-Sector	Key Products/Services	Typical Margins	Key Success Factors
Hospitals & Health Systems	Inpatient care, outpatient services, emergency, surgery	Operating margin 2-8%	Payer mix, occupancy rates, labor efficiency
Pharmaceuticals	Branded drugs, generics, biologics, vaccines	Gross margin 70-90%, Net 15-25%	R&D pipeline, patent life, pricing power
Medical Devices	Implants, diagnostics, surgical equipment, monitoring	Gross margin 60-75%	Clinical evidence, physician relationships
Health Insurance/Payers	Insurance products, pharmacy benefits, care management	Net margin 3-6%	Medical loss ratio, member acquisition
Pharmacy/PBM	Drug dispensing, specialty pharmacy, mail order	Gross margin 20-25%	Scale, rebate negotiations, generic substitution
Healthcare IT	EHR, analytics, telehealth, revenue cycle	SaaS margins 70-80%	Interoperability, switching costs
Diagnostics/Labs	Clinical testing, imaging, pathology	Gross margin 40-60%	Volume, automation, turnaround time

Based on our analysis of 800+ healthcare cases, the most common sub-sectors tested are hospitals (35%), pharmaceuticals (30%), and medical devices (20%).

Revenue Tree: Understanding Healthcare Economics

Healthcare revenue models differ fundamentally from typical B2C or B2B industries. The person receiving the service (patient) is often not the one paying (insurer/government).

Healthcare Revenue Equation

Healthcare Revenue = Volume × Reimbursement Rate × Collection Rate

Where:

• Volume = Number of services/procedures/prescriptions
• Reimbursement Rate = Negotiated or regulated payment per service
• Collection Rate = Actual collections as % of billed charges

flowchart TD
    A[Total Revenue] --> B[Patient Services]
    A --> C[Non-Patient Revenue]
    
    B --> D[Inpatient]
    B --> E[Outpatient]
    B --> F[Emergency]
    
    D --> D1[Admissions]
    D --> D2[Length of Stay]
    D --> D3[Case Mix Index]
    
    E --> E1[Visits]
    E --> E2[Procedures]
    E --> E3[Ancillary Services]
    
    C --> G[Research Grants]
    C --> H[Retail/Pharmacy]
    C --> I[Parking/Other]
    
    style A fill:#1e3a5f,color:#fff
    style B fill:#2563eb,color:#fff
    style C fill:#2563eb,color:#fff

Revenue by Payer Type

Understanding payer mix is essential — it directly impacts reimbursement rates and collection rates.

Payer Type	% of US Healthcare Spend	Typical Reimbursement vs. Charges	Collection Rate	Key Dynamics
Medicare	23%	40-60% of charges	95%+	Government-set rates, DRG-based for inpatient
Medicaid	17%	30-50% of charges	90-95%	State-administered, lowest rates
Commercial Insurance	34%	80-120% of charges	85-95%	Negotiated rates, highest reimbursement
Self-Pay/Uninsured	10%	100% of charges (billed)	10-30%	High bad debt risk
Other (VA, Workers Comp)	16%	Varies	Varies	Government programs

A hospital with 60% Medicare/Medicaid payer mix faces fundamentally different economics than one with 60% commercial — this is often a case-defining insight.

Pharmaceutical Revenue Model

Drug company revenue follows a different logic:

Pharma Revenue = Patients × Treatment Duration × Price × Market Share

Revenue Driver	Key Metrics	Benchmarks	Diagnostic Questions
Patient Pool	Disease prevalence, diagnosis rate	Varies by condition	Is this a common or rare disease?
Treatment Duration	Chronic vs. acute, cure vs. maintenance	Oncology: months; Chronic: years	How long do patients stay on therapy?
Price	WAC, ASP, net price after rebates	Specialty: $50K-500K/year; Generic: $10-100/year	Is pricing protected by patents?
Market Share	Competitive position, formulary status	Leader: 30-50%; Follower: 10-20%	What’s the competitive landscape?

Cost Structure: Where Healthcare Dollars Go

Hospital Cost Structure

pie title Hospital Cost Structure (% of Operating Expenses)
    "Labor" : 55
    "Supplies & Drugs" : 18
    "Purchased Services" : 10
    "Facilities & Equipment" : 8
    "Other" : 9

Cost Category	% of Revenue	Sub-Components	Optimization Levers
Labor	50-60%	Nursing (largest), physicians, technicians, admin	Staffing ratios, productivity, locum reduction
Supplies & Drugs	15-20%	Surgical supplies, pharmaceuticals, implants	GPO negotiation, standardization, formulary
Purchased Services	8-12%	Contract labor, IT, consulting, outsourced services	Insourcing evaluation, vendor consolidation
Facilities & Equipment	6-10%	Depreciation, maintenance, utilities, capital leases	Capacity utilization, energy efficiency
Bad Debt & Charity	3-8%	Uncompensated care, write-offs	Financial counseling, eligibility screening

Pharmaceutical Cost Structure

Cost Category	% of Revenue	Key Drivers	Industry Notes
R&D	15-25%	Drug discovery, clinical trials, regulatory	$2.6B average cost to bring a drug to market
Manufacturing (COGS)	20-30%	API, formulation, packaging, quality	Biologics have higher manufacturing costs
Sales & Marketing	20-30%	Sales reps, DTC advertising, physician outreach	US allows DTC; most countries do not
SG&A	10-15%	Corporate overhead, legal, compliance	Patent litigation is a major expense
Rebates & Discounts	20-40% of gross	PBM rebates, Medicaid best price, 340B	The gap between gross and net price

Key insight: Pharmaceutical “list price” and actual realized price can differ by 30-50% due to rebates and discounts. Always clarify which price is being discussed.

Competitive Landscape

Healthcare competition operates differently across sub-sectors due to regulation, local market dynamics, and the role of intermediaries.

Porter’s Five Forces for Healthcare

Force	Hospitals	Pharma	Medical Devices
Rivalry	Medium (local markets, consolidation)	High (patent cliffs, me-too drugs)	Medium-High (clinical differentiation)
New Entrants	Low (capital, CON laws, accreditation)	Medium (generics easy, branded hard)	Medium (regulatory barriers)
Supplier Power	Medium (GPOs, labor shortages)	Low (commodity APIs)	Low-Medium (raw materials)
Buyer Power	High (payers, employers)	High (PBMs, formularies)	Medium (hospital value analysis)
Substitutes	Medium (outpatient, home health)	High (generics, biosimilars, alternative therapies)	Medium (newer technologies)

Healthcare Competitive Response Framework

flowchart LR
    A[Competitive Threat] --> B{Response Type}
    B --> C[Clinical Differentiation]
    B --> D[Cost Leadership]
    B --> E[Access Strategy]
    B --> F[Vertical Integration]
    
    C --> C1[Quality outcomes, specialty programs]
    D --> D1[Scale, efficiency, standardization]
    E --> E1[Payer contracts, network inclusion]
    F --> F1[Own payer, pharmacy, ambulatory]
    
    style A fill:#1e3a5f,color:#fff
    style B fill:#2563eb,color:#fff

Customer Analysis

Healthcare “customers” are complex — multiple stakeholders influence purchasing decisions, and the end user (patient) often has limited choice.

Healthcare Stakeholder Map

Stakeholder	Role	Key Concerns	Influence on Decision
Patient	End user of care	Quality, access, out-of-pocket cost	Limited choice (especially for hospitals)
Physician	Prescriber/decision-maker	Clinical efficacy, ease of use, liability	High (especially for devices, drugs)
Payer (Insurance)	Financing and gatekeeping	Cost, outcomes, network management	Very high (formulary, prior auth, network)
Hospital/Health System	Care delivery platform	Margin, quality scores, patient volume	High for supplies, services
PBM	Pharmacy benefit intermediary	Rebates, formulary control, mail order	Very high for drug access
Employer	Plan sponsor	Total cost of care, employee satisfaction	Increasing (direct contracting)
Regulator	Approval and oversight	Safety, efficacy, compliance	Gate-keeping (FDA, CMS)

Patient Segmentation

Segment	Characteristics	Healthcare Utilization	Strategic Implications
Healthy/Low Utilizers	<2 visits/year, minimal Rx	Low cost, high profit for payers	Wellness, prevention focus
Chronic Disease	Diabetes, heart disease, asthma	Moderate-high, predictable	Care management, medication adherence
High-Cost/Complex	Multiple conditions, frequent hospitalization	Very high, 5% of patients = 50% of costs	Intensive care coordination
Acute Episodic	Surgery, injury, pregnancy	Concentrated, plannable	Bundled payments, centers of excellence

Distribution Channels

Healthcare distribution is highly regulated and varies significantly by product type.

Drug Distribution Channel

flowchart LR
    A[Manufacturer] --> B[Wholesaler]
    B --> C1[Retail Pharmacy]
    B --> C2[Hospital Pharmacy]
    B --> C3[Specialty Pharmacy]
    B --> C4[Mail Order]
    
    C1 --> D[Patient]
    C2 --> D
    C3 --> D
    C4 --> D
    
    A --> E[PBM]
    E --> C1
    E --> C3
    E --> C4
    
    style A fill:#1e3a5f,color:#fff
    style E fill:#dc2626,color:#fff
    style D fill:#1e3a5f,color:#fff

Channel Economics

Channel	Margin to Intermediary	Volume	Control/Access	Best For
Hospital Direct	5-15%	High	High formulary control	High-cost, administered drugs
Retail Pharmacy	15-25%	Very High	Limited control	Generics, common Rx
Specialty Pharmacy	20-30%	Low	High patient support	Biologics, complex therapies
Mail Order	10-20%	High	PBM controlled	Chronic, maintenance drugs
Physician Office (Buy & Bill)	20-30% markup	Medium	Physician choice	Injectable drugs, vaccines

Supply Chain

Healthcare supply chains are complex, highly regulated, and increasingly global.

Hospital Supply Chain

Category	% of Supply Spend	Key Players	Strategic Considerations
Medical/Surgical Supplies	40-50%	Cardinal, Medline, Owens & Minor	GPO contracts, standardization
Pharmaceuticals	30-40%	McKesson, AmerisourceBergen, Cardinal	340B eligibility, specialty drugs
Implants & High-Cost Devices	15-20%	Medtronic, J&J, Stryker	Physician preference items
Capital Equipment	5-10%	GE, Siemens, Philips	Long replacement cycles

Pharmaceutical Supply Chain Metrics

Metric	Definition	Benchmark	Significance
Days of Inventory	Average inventory / Daily COGS	60-90 days	Working capital efficiency
OTIF (On-Time In-Full)	% orders delivered complete and on time	98%+	Service level
Cold Chain Compliance	% shipments maintaining temperature	99.9%+	Critical for biologics
Recall Response Time	Time to remove recalled product	<24 hours	Patient safety
Supply Continuity Rate	% time without stockouts	99.5%+	Drug shortage prevention

Key Industry Trends

These trends frequently appear in healthcare cases and are important context for any recommendation.

Trend	Impact	Case Relevance	Key Data
Value-Based Care Shift	Moving from fee-for-service to outcomes-based payment	Provider strategy, payer cases	40% of payments now have value component
Consolidation	Horizontal and vertical M&A across healthcare	M&A cases, market entry	Top 10 health systems now control 25% of beds
Drug Pricing Pressure	Government and payer pushback on high prices	Pharma pricing, market access	IRA caps Medicare drug costs; state price controls expanding
Workforce Crisis	Nursing and clinician shortages	Operations, labor strategy	200,000+ nurse shortage projected by 2030
Digital Health & AI	Telehealth, AI diagnostics, remote monitoring	Technology strategy, new products	Telehealth visits up 38x since 2019 (though normalizing)
Specialty Drug Growth	Shift from primary care to specialty therapies	Pharma strategy, distribution	Specialty drugs: 2% of Rx volume but 50%+ of spend

Important Terminology

Master these terms before your healthcare case interview:

Reimbursement & Payment Terms

Term	Definition	Usage Context
DRG (Diagnosis Related Group)	Payment classification grouping similar cases	Hospital inpatient reimbursement
CPT Code	Procedure code used for billing	Physician/outpatient billing
RVU (Relative Value Unit)	Measure of physician work/resource use	Physician compensation
MLR (Medical Loss Ratio)	% of premiums spent on medical care	Payer profitability (must be >80%)
PMPM (Per Member Per Month)	Monthly cost per enrolled member	Payer/capitation discussions
ASP (Average Sales Price)	Average price Medicare uses for Part B drugs	Drug reimbursement
AWP (Average Wholesale Price)	Benchmark price for drugs	Often called “Ain’t What’s Paid”

Clinical & Operational Terms

Term	Definition	Usage Context
Case Mix Index (CMI)	Average complexity of patients treated	Hospital acuity/reimbursement
Length of Stay (LOS)	Average days per hospital admission	Efficiency metric
HCAHPS	Patient satisfaction survey (required)	Quality scores
Readmission Rate	% patients returning within 30 days	Quality penalty trigger
FTE	Full-Time Equivalent (for staffing)	Labor productivity
Prior Authorization	Payer approval required before treatment	Access/coverage decisions

Pharmaceutical Terms

Term	Definition	Usage Context
NDA/BLA	New Drug Application / Biologics License Application	FDA approval process
ANDA	Abbreviated NDA (for generics)	Generic drug entry
WAC (Wholesale Acquisition Cost)	Manufacturer list price	Baseline for discounts
Rebate	Discount paid after sale to PBM/payer	Net price calculation
Formulary	List of drugs covered by a plan	Market access
Step Therapy	Requirement to try cheaper drugs first	Access restriction
Patent Cliff	Revenue drop when patents expire	Lifecycle management

Important Calculations

These calculations frequently appear in healthcare cases.

Hospital Profitability

Operating Margin = (Operating Revenue - Operating Expenses) / Operating Revenue

• Average hospital: 2-4%
• Top quartile: 8-12%

Net Patient Revenue per Adjusted Discharge = Net Patient Revenue / (Discharges + Outpatient Equivalents)

• Varies by region: $12,000-$20,000

Labor Cost per Adjusted Patient Day = Total Labor Cost / Adjusted Patient Days

• Benchmark: $1,500-$2,500

Occupancy Rate = Patient Days / (Beds × 365)

• Target: 70-85% (too high = capacity strain)

Pharmaceutical Economics

Gross-to-Net Discount = (WAC Price - Net Realized Price) / WAC Price × 100

• Ranges from 20% (protected specialty) to 80%+ (competitive generics)

Cost per Patient per Year = Annual Dose × Doses per Year × Net Price per Dose

• Used for budget impact analysis

QALY (Quality-Adjusted Life Year) = Years of life × Quality weight (0-1)

• $50,000-$150,000 per QALY is typical threshold for cost-effectiveness

Patent Remaining Life Value = NPV of remaining patent-protected revenues

• Critical for M&A valuation

Payer Economics

Medical Loss Ratio = (Medical Costs + Quality Improvement) / Premium Revenue

• ACA requires: 80% individual/small group, 85% large group

Combined Ratio = Medical Loss Ratio + Administrative Cost Ratio

• Target: <100% (otherwise losing money)

PMPM (Per Member Per Month) = Total Cost / (Members × Months)

• Allows comparison across different plan sizes

Important Considerations

These are the factors that separate strong candidates from average ones in healthcare cases.

Common Pitfalls

1. Ignoring the Payer Mix: A 5% Medicare rate cut has different impact depending on payer mix. Always ask about payer composition.

2. Forgetting Regulation: Healthcare is heavily regulated. Market entry, pricing changes, and new products all face regulatory hurdles.

3. Confusing Price with Revenue: Drug “price increases” may not translate to revenue growth if rebates increase proportionally.

4. Overlooking Stakeholder Complexity: The buyer isn’t the user isn’t the payer. Map all stakeholders before recommending.

5. Assuming National Scale: Healthcare is often local. A strategy that works in one market may not transfer to another.

Questions to Always Ask

• What type of healthcare entity is this (hospital, pharma, device, payer)?
• What is the payer mix or customer composition?
• Is this a regulated product/service? What approvals are needed?
• Who makes the purchasing decision (physician, hospital, payer, patient)?
• What is the competitive landscape? Are there patent or exclusivity protections?
• What are the key quality/outcome metrics being tracked?

Red Flags in Healthcare Cases

Signal	What It Suggests	Follow-Up Analysis
Operating margin declining despite volume growth	Payer mix shift or cost inflation	Analyze margin by payer, labor cost trends
High gross-to-net spread increasing	Competitive pressure, rebate demands	Evaluate pricing sustainability, formulary status
Readmission rates above benchmark	Quality issues, care coordination gaps	Assess discharge process, post-acute partnerships
Physician alignment declining	Compensation, administrative burden	Survey physicians, compare to market
Drug pipeline concentrated	Risk if trials fail	Assess portfolio diversification, BD opportunities

Key Takeaways

• Healthcare cases require immediate sub-sector identification — hospitals, pharma, devices, and payers have fundamentally different economics
• Revenue follows the equation: Volume × Reimbursement × Collection; always ask about payer mix
• Labor is 50-60% of hospital costs; R&D is 15-25% of pharma revenue — know the cost structures cold
• Multiple stakeholders influence healthcare decisions: map the patient, physician, payer, and regulator roles
• Regulation shapes everything: FDA approvals, CMS reimbursement rules, and state-level requirements matter
• Key metrics by sub-sector: operating margin for hospitals, gross-to-net for pharma, MLR for payers
• Trends to know: value-based care shift, consolidation, workforce shortages, specialty drug growth

Ready to practice? Browse healthcare industry cases in our case library, or test your framework in a timed AI Mock Interview to build speed and confidence.